Hepatocellular carcinoma after prior sorafenib treatment: incidence, healthcare utilisation and costs from German statutory health insurance claims data

Hepatocellular carcinoma after prior sorafenib treatment: incidence, healthcare utilisation and costs from German statutory health insurance claims data

Abstract Objective To estimate both the number of patients with hepatocellular carcinoma (HCC) eligible annually for second-line therapy following sorafenib in Germany and the healthcare costs accrued by patients meeting eligibility criteria. Methods Patients with an HCC diagnosis and one or more so...

Full description

Bibliographic Details
Main Authors: Johannes Clouth, Astra M. Liepa, Guido Moeser, Heiko Friedel, Magdalena Bernzen, Jörg Trojan, Elena Garal-Pantaler
Format: Article
Language:English
Published: BMC 2018-08-01
Series:Health Economics Review
Subjects:
Hepatocellular carcinoma
Germany
Second line
Sorafenib
Health economics
German statutory health insurance claims data
Online Access:http://link.springer.com/article/10.1186/s13561-018-0199-1

Internet

http://link.springer.com/article/10.1186/s13561-018-0199-1

Similar Items